Alidzhanova Kh G, Eliseev A O, Tvorogova M G, Buriachkovskaia L I, Chuĭkin N A, Tripol'skaia L V, Kukharchuk V V
Ter Arkh. 1997;69(8):13-7.
Patients with heterozygous family hypercholesterolemia (HFH) were divided into two groups. Group 1 patients received lovastatin in a daily dose 40-60-80 mg under control of lipids and peripheral blood biochemistry. In 17 patients lovastatin was given as monotherapy, in 15 patients it was combined with plasmapheresis. No hypolipidemic therapy was given to ten patients of group 2. The treatment and follow-up lasted for 4.1 +/- 1.9 years, on the average. A marked hypolipidemic effect was seen in the comorbid therapy. 43% of the patients became resistant to lovastatin, the resistance developed more frequently in monotherapy. The blood fibrinogen fell by 40%, spontaneous and induced platelet aggregation returned to normal, being somewhat higher in subjects resistant to lovastatin therapy. The study shows that hypolipidemic therapy has reduced the risk of IHD fatal complications and progression of non-coronary atherosclerosis in patients of group 1.
杂合子家族性高胆固醇血症（HFH）患者被分为两组。第1组患者在血脂和外周血生化指标监测下，接受每日剂量为40 - 60 - 80毫克的洛伐他汀治疗。17例患者接受洛伐他汀单一疗法，15例患者接受洛伐他汀与血浆置换联合治疗。第2组的10例患者未接受任何降血脂治疗。治疗和随访平均持续4.1±1.9年。联合治疗显示出显著的降血脂效果。43%的患者对洛伐他汀产生耐药性，单一疗法中耐药性出现得更为频繁。血纤维蛋白原下降了40%，自发性和诱导性血小板聚集恢复正常，对洛伐他汀治疗耐药的患者中这一指标略高。研究表明，降血脂治疗降低了第1组患者发生缺血性心脏病致命并发症和非冠状动脉粥样硬化进展的风险。
